Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Highlights from the first-ever Neural Genetics and Epigenetics Gordon Research Conference
The meeting’s organizers recap the science to watch.
Highlights from the first-ever Neural Genetics and Epigenetics Gordon Research Conference
The meeting’s organizers recap the science to watch.
Cortical territories compete in developmental space race
Sensory and association regions are established through a reciprocal process, according to a new model of cortical development.
Cortical territories compete in developmental space race
Sensory and association regions are established through a reciprocal process, according to a new model of cortical development.
Dendrites compute independently of cell body
Depending on their distance from the cell body, dendrites play different roles in learning and memory.
Dendrites compute independently of cell body
Depending on their distance from the cell body, dendrites play different roles in learning and memory.